For instance, EGFR antagonists, which are effective in lung carcinoma (as stated before) due to mutations of the kinase domain, have been disappointing in glioblastoma, where mutations of the extracellular domain are largely implicated. The gene discussed is EGFR; the disease is glioblastoma.